Health Canada Approves Vyxeos?, the First Chemotherapy Advance in over 40 years for Adults with High-risk Acute Myeloid Leukemia (AML)
- allergic to daunorubicin or cytarabine, or to any of the other ingredients of this drug.
1?Jazz Pharmaceuticals Canada Inc.?Vyxeos??(daunorubicin and cytarabine liposome for injection) Product Monograph.?April 28, 2021. Available at:?https://pp.jazzpharma.com/pi/vyxeos.ca.PM-en.pdf?? Accessed?May 30, 2021. |
|||||
2?LLSC. Acute Myeloid Leukemia.? Available at:?https://www.llscanada.org/leukemia/acute-myeloid-leukemia#:~:text=Acute%20myeloid%20leukemia%20(AML),a%20difficult%20disease%20to%20treat.? Accessed?May 31, 2021. |
|||||
3?Russell N, Cluzeau T, McLornan D et al. Outcomes for Patients with High-Risk Acute Myeloid Leukaemia: Can We Move From Months to Years? Symposium and poster presentation at: EHA;?June 11, 2020; Available at:?https://emj.emg-health.com/wp-content/uploads/sites/2/2020/07/Outcomes-for-Patients-with-High-Risk-Acute-Myeloid-Leukaemia-Can-We-Move-from-Months-to-Years.pdf |
|||||
4?Canadian Cancer Society. Acute Mylogenous Leukemia statistics. Available at:?https://www.cancer.ca/en/cancer-information/cancer-type/leukemia-acute-myelogenous-aml/statistics/?region=on#:~:text=Incidence%20and%20mortality&text=Mortality%20is%20the%20number%20of,diagnosed%20with%20acute%20myelogenous%20leukemia.? Accessed?May 31, 2021. |
|||||
5?Shysh, A.C., Nguyen, L.T., Guo, M.?et al.?The incidence of acute myeloid leukemia in?Calgary, Alberta, Canada: a retrospective cohort study.?BMC Public Health?18,?94 (2018). Available at:?https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-017-4644-6? Accessed?May 31, 2021. |
|||||
6?Trialsitenews.com. Beat AML Master Clinical Trial Shows First Treatment Advance in 40 Years. Available at:?https://trialsitenews.com/beat-aml-master-clinical-trial-shows-first-treatment-advance-in-40-years/? Accessed?May 31, 2021. |
|||||
7?Vyxeos.com. Mechanism of Delivery. Available at:?https://vyxeospro.com/mechanism-of-delivery/? Accessed?May 31, 2021. |
|||||
8?Tolcher AW. Mayer LD. Improving combination cancer chemotherapy: the CombiPlex??development platform. Future Oncol. 2018; 14(13), 1317-1332. |